Preclinical rationale for entinostat in embryonal rhabdomyosarcoma

BACKGROUND: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in the pediatric cancer population. Survival among metastatic RMS patients has remained dismal yet unimproved for years. We previously identified the class I-specific histone deacetylase inhibitor, entinostat (ENT), as a pharm...

Descripción completa

Detalles Bibliográficos
Autores principales: Bharathy, Narendra, Berlow, Noah E., Wang, Eric, Abraham, Jinu, Settelmeyer, Teagan P., Hooper, Jody E., Svalina, Matthew N., Bajwa, Zia, Goros, Martin W., Hernandez, Brian S., Wolff, Johannes E., Pal, Ranadip, Davies, Angela M., Ashok, Arya, Bushby, Darnell, Mancini, Maria, Noakes, Christopher, Goodwin, Neal C., Ordentlich, Peter, Keck, James, Hawkins, Douglas S., Rudzinski, Erin R., Mansoor, Atiya, Perkins, Theodore J., Vakoc, Christopher R., Michalek, Joel E., Keller, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528217/
https://www.ncbi.nlm.nih.gov/pubmed/31113472
http://dx.doi.org/10.1186/s13395-019-0198-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528217/
https://www.ncbi.nlm.nih.gov/pubmed/31113472
http://dx.doi.org/10.1186/s13395-019-0198-x

Ejemplares similares